Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study.

Crombet, T; Torres, O; Rodríguez, V; Menéndez, A; Stevenson, A; Ramos, M; Torres, F; Figueredo, R; Veitía, I; Iznaga, N; Pérez, R; Lage, A

Crombet, T; Torres, O; Rodríguez, V; Menéndez, A; Stevenson, A; Ramos, M; Torres, F; Figueredo, R; Veitía, I; Iznaga, N; Pérez, R; Lage, A.

Affiliation

Crombet T; Center of Molecular Immunology, Havana, Cuba. Taniac@ict.cim.sld.cu

Hybridoma ; 20(2): 131-6, 2001 Apr.

Article in En | MEDLINE | ID: mdl-11394532

Subject(s)

Antibodies, Monoclonal/administration & dosage; Brain Neoplasms/diagnostic imaging; Brain Neoplasms/drug therapy; ErbB Receptors/immunology; Adult; Animals; Antibodies, Monoclonal/therapeutic use; Antibodies, Monoclonal/toxicity; Astrocytoma/complications; Astrocytoma/diagnostic imaging; Astrocytoma/drug therapy; Astrocytoma/metabolism; Brain Neoplasms/complications; Brain Neoplasms/metabolism; Dose-Response Relationship, Drug; ErbB Receptors/metabolism; Female; Humans; Male; Meningioma/complications; Meningioma/diagnostic imaging; Meningioma/drug therapy; Meningioma/metabolism; Mice; Middle Aged; Radioimmunodetection; Technetium; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / ErbB Receptors / Antibodies, Monoclonal Limits: Adult / Animals / Female / Humans / Male / Middle aged Language: En Journal: Hybridoma Year: 2001 Document type: Article Affiliation country: Cuba Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links